thepharmaletter
Article | 19 November 2010
The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for drug giant Merck & Co’s (NYSE: MRK) Gardasil ([Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females aged nine through 26 years.
Please note that SANE Vax is noted to the immediate right of this headline.
Leave a Reply